United Therapeutics Corporation
UTHR
$301.42
-$6.58-2.14%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.99B | 2.88B | 2.76B | 2.62B | 2.50B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.99B | 2.88B | 2.76B | 2.62B | 2.50B |
| Cost of Revenue | 329.30M | 309.70M | 304.80M | 291.80M | 278.10M |
| Gross Profit | 2.66B | 2.57B | 2.45B | 2.32B | 2.22B |
| SG&A Expenses | 666.10M | 640.40M | 607.20M | 580.70M | 533.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.00M | 3.80M | 3.80M | 3.80M | 3.80M |
| Total Operating Expenses | 1.52B | 1.43B | 1.41B | 1.36B | 1.24B |
| Operating Income | 1.47B | 1.44B | 1.34B | 1.26B | 1.25B |
| Income Before Tax | 1.56B | 1.54B | 1.44B | 1.40B | 1.38B |
| Income Tax Expenses | 353.20M | 343.90M | 327.00M | 331.70M | 330.50M |
| Earnings from Continuing Operations | 1.21K | 1.20K | 1.11K | 1.07K | 1.05K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.21B | 1.20B | 1.11B | 1.07B | 1.05B |
| EBIT | 1.47B | 1.44B | 1.34B | 1.26B | 1.25B |
| EBITDA | 1.55B | 1.52B | 1.41B | 1.32B | 1.31B |
| EPS Basic | 27.11 | 26.46 | 24.34 | 23.11 | 22.38 |
| Normalized Basic EPS | 22.92 | 22.18 | 20.13 | 18.55 | 18.03 |
| EPS Diluted | 25.05 | 24.59 | 22.76 | 21.75 | 21.14 |
| Normalized Diluted EPS | 21.18 | 20.61 | 18.82 | 17.47 | 17.04 |
| Average Basic Shares Outstanding | 178.60M | 180.70M | 183.00M | 185.30M | 187.80M |
| Average Diluted Shares Outstanding | 193.20M | 194.30M | 195.40M | 196.70M | 198.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |